← All trials
NCT01467882
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2012
- Primary completion
- Aug 1, 2013
- Completion date
- Jul 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 44
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- DebiopharmLead sponsor
- Nancy Wright MD P.A., Tallahasse, FloridaOverall official - principal investigator
- Barry J. Reiner, MD, LLC, Baltimore, MarylandOverall official - principal investigator
- SRCR, Inc, Bell Gardens, CaliforniaOverall official - principal investigator
- Endocrine Associates of Dallas, Plano, TexasOverall official - principal investigator
- Pediatric Endocrine Associates, Atlanta, GeorgiaOverall official - principal investigator
- Alzohaili Medical Consultants, Dearborn, MichiganOverall official - principal investigator
- Van Meter Pediatric Endocrinology, Peachtree City, GeorgiaOverall official - principal investigator
- University of ArizonaOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Rutgers UniversityOverall official - principal investigator
- Pennsylvania State UniversityOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- St. Barnabas Medical Center, Livingston, NJOverall official - principal investigator
- Louisiana State UniversityOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- State University of New York, BuffaloOverall official - principal investigator
- University of ChileOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- Arnold Palmer Hospital for ChildrenOverall official - principal investigator
- Children's National Medical CenterOverall official - principal investigator
- Lynn Health Science InstituteOverall official - principal investigator
- University of Monterrey, MexicoOverall official - principal investigator
- University of RochesterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.